Par Pharmaceutical

Par Pharmaceutical Companies, Inc. develops, manufactures, and markets generic drugs and innovative branded pharmaceuticals for specialty markets. In July 2005, Par received approval for and introduced Megace® ES, the company's first branded pharmaceutical product. We expect to launch our second branded product some time in 2006. Our Generic Products Division is committed to providing high-quality pharmaceuticals that are affordable and accessible to patients. Par ranks fifth in sales among all U.S. generic companies, according to IMS Health. We currently manufacture, market, or license more than 110 prescription drug products.
Par has 59 products awaiting FDA approval and more than 60 other products in various stages of development. In 2005 the company completed the integration of Kali Laboratories, Inc. into the Par structure, which significantly increased Par's generic research and development capabilities. With the acquisition and integration of Kali Laboratories, Par now has one of the most promising new product pipelines in the generic drug industry. Par's generic drug portfolio includes central nervous system, cardiovascular, anti-inflammatory, gastrointestinal, and anti-infective therapeutics.

Contact Details: 300 Tice Boulevard Woodcliff Lake New Jersey 07677 United States of America Tel: 201 802 4000 Fax: Email: WWW: www.parpharm.com/

Loading...

Recent Publications by Par Pharmaceutical:
The science of megestrol acetate delivery: potential to improve outcomes in cachexia. Cachexia, usually defined as the loss of >5% of an individual's baseline...	22nd September, 2005	Scientific and Regulatory Affairs, Par Pharmaceutical, Inc., Spring	BioDrugs. 2005;19(3):179-87.

Press Releases on Par Pharmaceutical:
Par Pharmaceutical to Host Analyst Day on December 3rd	16th November, 2009	Par Pharmaceutical Companies, Inc.	WOODCLIFF LAKE, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) will hold an Analyst Day from 9:00am to 12:00pm EST on December 3, 2009 at its Spring Valley, NY
Par Pharmaceutical Receives Final Approval to Market Generic Ultram(R) ER	16th November, 2009	Par Pharmaceutical Companies, Inc.	WOODCLIFF LAKE, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it has received final approval from the U.S. Food and Drug Administration
Par Pharmaceutical Reports EPS of $0.76 for Third Quarter 2009	6th November, 2009	Par Pharmaceutical Companies	-- Metoprolol: For the quarter ended October 3, 2009, net sales of metoprolol succinate were $161.1 million, a decrease of 47% from the second quarter 2009. The decrease was
Par Pharmaceutical to Host Third Quarter 2009 Earnings Conference Call On November 6 at 9:00 am	22nd October, 2009	Par Pharmaceutical Companies, Inc.	WOODCLIFF LAKE, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it will host a conference call and live webcast on Friday, November 6, 2009
Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA	16th June, 2009	Par Pharmaceutical Companies, Inc.	WOODCLIFF LAKE, N.J., June 16 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX),

BioNews Results for Par Pharmaceutical:
Into the Hot Seat	GenomeWeb:  Nov 12 2009 6:20PM Matching: par pharmaceutical
Research and Markets: The Pharmaceutical Market: Australia	RBC Dain Rauscher:  Nov 12 2009 11:16AM Matching: par pharmaceutical
Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Ten	Freshnews.com:  Nov 10 2009 12:00AM Matching: par pharmaceutical
Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Ten	TickerTech.com:  Nov 10 2009 3:20AM Matching: par pharmaceutical
Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for 'Modified Dutch Auction' Ten	Atlanta Business Chronicle:  Nov 9 2009 11:50PM Matching: par pharmaceutical
Promote your company here: BioNewsCast - Press Release Distribution	→View more Par Pharmaceutical news.

Par Pharmaceutical Patents:
US Patent No.	Title
7552020	System and method for sorting data
7246020	System and method for sorting data
6593486	Process for making cyanomethyl ester precursors of flecainide

Par Pharmaceutical (PRX) Financial information Links from Barchart
PRX Quote from from Barchart.com
PRX Chart from from Barchart.com
PRX Profile from from Barchart.com
PRX Opinion from from Barchart.com
→View more Par Pharmaceutical finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 558 times since April 2007, the link to the organisation's website has been followed 85 times

Recent Search Terms used to find this page: par excell pharmaceutical trial | strativa pdf | central nervous system pharmaceutical companies in nj | what drug is par | pharmaceutical companies websites which has tender lists | par pharmaceuticals | par pharma canada | par pharmaceuticals | par pharmaceuticals | par pharmaceutical email | .

Search for more companies in Woodcliff Lake

Search for more companies in New Jersey

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Par Pharmaceutical